Emergence Capital

Emergence Therapeutics is a European biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for high-unmet-need cancers. The company's lead program, ETX-22, is a Nectin-4 targeting ADC designed to deliver a potent cytotoxic payload with improved selectivity and a wider therapeutic window compared to existing treatments. Emergence's technology emphasizes site-specific conjugation and optimized linker-payload combinations to enhance efficacy and reduce off-target toxicity. In June 2023, the company was acquired by Eli Lilly and Company to bolster Lilly's oncology pipeline and ADC capabilities.